Immunocore(IMCR)
OXFORDSHIRE, United KingdomBiotechnology
Focus: Immunocore is a UK-based public biotech specializing in T Cell Receptor (TCR) fragment therapies for oncology and infectious diseases. The company has achieved commercial validation with KIMMTRAK's FDA approval for uveal melanoma and maintains a clinical-stage pipeline of 18+ programs.
Profile data last refreshed 19h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
0
About Immunocore
AI assessmentNot HiringNo open roles listed right now. Follow Immunocore to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Late-stage
3 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Revenue
$249M
Key Products
Growing
Peak
First-in-class approved TCR-fragment therapy validating platform; driving revenue growth (+43% YoY: $174M→$249M FY24-25).
Products & Portfolio (1)
Help build intelligence for Immunocore
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.